Optimizing Blood-Stage Vaccines: Essential Tools in Malaria Eradication Strategies
Abstract
Malaria continues to be a major threat to global health, taking a significant toll on mortality rates. Although numerous strategies for combating malaria are actively evolving, none has successfully eradicated the disease. Vaccines against malaria present a reliable approach; licensed liver-stage vaccines have opened a new era in malaria control but because they are not fully effective, a complementary blood-stage vaccine is needed. This review explores the pivotal role of blood-stage vaccines as formidable weapons in the ongoing battle against malaria by elucidating their profound impact on malaria-linked morbidity and mortality. The immunological mechanisms through which blood-stage vaccines mediate significant reductions in disease burden and interrupt transmission dynamics are crucial in vaccine design. Thus, they have been examined in this review. In the context of blood-stage malaria, specific antigens are critical to the survival and replication of the parasite, playing essential roles in the invasion of erythrocytes. As a result, these antigens present highly promising vaccine candidates that can stop the invasion in various ways, such as the binding of sialic acid residues by EBA175 or the hydrolysing effect of MSP1. Polymorphism challenges hinder blood-stage vaccine development but enhancing current candidates and identifying novel erythrocytic antigens offer a promising path to a malaria-free world. This multifaceted approach aims to fortify the immune response against the Plasmodium parasite, thereby advancing global eradication efforts.
Keywords: Malaria; Plasmodium,;Vaccine; Blood-stage
Full Text:
PDFReferences
Anteneh M, Asres MS, Legese GL, Alemayehu MA, Woldesenbet D, et al. Treatment outcomes and associated factors in severe malaria patients at University of Gondar Hospital, Northwest Ethiopia: A retrospective study (2020–2023). Plos one, (2024); 19(12): e0309681.
Alkurbi MO. Plausible inhibitors of malaria parasite Plasmodium falciparum 3D7 ATP-dependent DNA helicase. Advancements in Life Sciences, (2024); 10(4): 644-650.
Pirahmadi S, Afzali S, Zargar M, Zakeri S, Mehrizi AA. How can we develop an effective subunit vaccine to achieve successful malaria eradication? Microbial Pathogenesis, (2021); 160(1): 105203.
Etefia E, Inyang-Etoh P. Malaria Vaccine Development: Challenges and Prospects. Medical and Pharmaceutical Journal, (2023); 2(1): 28-42.
Datoo MS, Natama HM, Some A, Bellamy D, Traore O, et al. Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial. The Lancet Infectious Diseases, (2022); 22(12): 1728-1736.
Aminu MA, Ur Rehman A, Azizan NA, Othman AS. Malaria and Cardiometabolic Health: A Review of Its Impact on Metabolic and Cardiovascular Disorders. Malaysian Journal of Medicine & Health Sciences, (2024); 20(10): 242-251.
Cowman AF, Healer J, Marapana D, Marsh K. Malaria: Biology and Disease. Cell, (2016); 167(3): 610-624.
Barry A, Hansen D. Naturally acquired immunity to malaria. Parasitology, (2016); 143(2): 125-128.
Othman AS, Marin-Mogollon C, Salman AM, Franke-Fayard BM, Janse CJ, et al. The use of transgenic parasites in malaria vaccine research. Expert review of vaccines, (2017); 16(7): 685-697.
Wu Y, Sinden RE, Churcher TS, Tsuboi T, Yusibov V. Development of malaria transmission-blocking vaccines: from concept to product. Adv Parasitol, (2015); 89109-152.
Khoury DS, Aogo R, Randriafanomezantsoa-Radohery G, McCaw JM, Simpson JA, et al. Within-host modeling of blood-stage malaria. Immunol Rev, (2018); 285(1): 168-193.
Chan J-A, Fowkes FJ, Beeson JG. Surface antigens of Plasmodium falciparum-infected erythrocytes as immune targets and malaria vaccine candidates. Cellular and Molecular Life Sciences, (2014); 713633-3657.
Langhorne J, Ndungu FM, Sponaas A-M, Marsh K. Immunity to malaria: more questions than answers. Nature immunology, (2008); 9(7): 725-732.
Freund J, Thomson KJ, et al. Immunization of monkeys against malaria by means of killed parasites with adjuvants. American Journal of Tropical Medicine, (1948); 28(1): 1-22.
McCarthy JS, Good MF. Whole parasite blood stage malaria vaccines: a convergence of evidence. Human Vaccines, (2010); 6(1): 114-123.
Coggeshall LT, Kumm HW. Demonstration of Passive Immunity in Experimental Monkey Malaria. The Journal of Experimental Medicine, (1937); 66(2): 177-190.
Good MF, Miller LH. Interpreting challenge data from early phase malaria blood stage vaccine trials. Expert Rev Vaccines, (2018); 17(3): 189-196.
Cohen S, Mc GI, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature, (1961); 192733-737.
Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. The Journal of experimental medicine, (1990); 172(6): 1633-1641.
Mitchell GH, Richards WH, Butcher GA, Cohen S. Merozoite vaccination of douroucouli monkeys against falciparum malaria. Lancet, (1977); 1(8026): 1335-1338.
Trager W, Jensen JB. Human malaria parasites in continuous culture. Science, (1976); 193(4254): 673-675.
Brake DA, Weidanz WP, Long CA. Antigen-specific, interleukin 2-propagated T lymphocytes confer resistance to a murine malarial parasite, Plasmodium chabaudi adami. Journal of Immunology, (1986); 137(1): 347-352.
Amante FH, Good MF. Prolonged Th1‐like response generated by a Plasmodium yoeli‐specific T cell clone allows complete clearance of infection in reconstituted mice. Parasite immunology, (1997); 19(3): 111-126.
Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet, (2002); 360(9333): 610-617.
Duffy PE. Current approaches to malaria vaccines. Current Opinion in Microbiology, (2022); 70102227.
Muh F, Lee SK, Hoque MR, Han JH, Park JH, et al. In vitro invasion inhibition assay using antibodies against Plasmodium knowlesi Duffy binding protein alpha and apical membrane antigen protein 1 in human erythrocyte-adapted P. knowlesi A1-H.1 strain. Malaria Journal, (2018); 17(1): 272.
Healer J, Chiu CY, Hansen DS. Mechanisms of naturally acquired immunity to P. falciparum and approaches to identify merozoite antigen targets. Parasitology, (2018); 145(7): 839-847.
Ord RL, Rodriguez M, Lobo CA. Malaria invasion ligand RH5 and its prime candidacy in blood-stage malaria vaccine design. Human Vaccines & Immunotherapeutics, (2015); 11(6): 1465-1473.
Crosnier C, Bustamante LY, Bartholdson SJ, Bei AK, Theron M, et al. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature, (2011); 480(7378): 534-537.
Douglas AD, Baldeviano GC, Lucas CM, Lugo-Roman LA, Crosnier C, et al. A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys. Cell host & microbe, (2015); 17(1): 130-139.
Oboh MA, Asmorom N, Falade C, Ojurongbe O, Thomas BN. High genetic and haplotype diversity in vaccine candidate Pfceltos but not Pfrh5 among malaria-infected children in Ibadan, Nigeria. PeerJ, (2023); 11e16519.
Jamwal A, Constantin CF, Hirschi S, Henrich S, Bildl W, et al. Erythrocyte invasion-neutralising antibodies prevent Plasmodium falciparum RH5 from binding to basigin-containing membrane protein complexes. Elife, (2023); 12e83681.
Miura K, Diouf A, Fay MP, Barrett JR, Payne RO, et al. Assessment of precision in growth inhibition assay (GIA) using human anti-PfRH5 antibodies. Malaria Journal, (2023); 22(1): 159.
Villasis E, Lopez-Perez M, Torres K, Gamboa D, Neyra V, et al. Anti-Plasmodium falciparum invasion ligand antibodies in a low malaria transmission region, Loreto, Peru. Malaria Journal, (2012); 11(1): 361.
Douglas AD, Williams AR, Illingworth JJ, Kamuyu G, Biswas S, et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nature communications, (2011); 2(1): 601.
Tran TM, Ongoiba A, Coursen J, Crosnier C, Diouf A, et al. Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria. The Journal of Infectious Diseases, (2014); 209(5): 789-798.
Chiu CY, Healer J, Thompson JK, Chen L, Kaul A, et al. Association of antibodies to Plasmodium falciparum reticulocyte binding protein homolog 5 with protection from clinical malaria. Frontiers in Microbiology, (2014); 5314.
Chua CY, Lee PC, Lau TY. Analysis of polymorphisms and selective pressures on ama1 gene in Plasmodium knowlesi isolates from Sabah, Malaysia. Journal of Genetics, (2017); 96(4): 653-663.
Ouattara A, Niangaly A, Adams M, Coulibaly D, Kone AK, et al. Epitope-based sieve analysis of Plasmodium falciparum sequences from a FMP2. 1/AS02A vaccine trial is consistent with differential vaccine efficacy against immunologically relevant AMA1 variants. Vaccine, (2020); 38(35): 5700-5706.
Milán-Noris EM, Monreal-Escalante E, Rosales-Mendoza S, Soria-Guerra RE, Radwan O, et al. An AMA1/MSP1 19 Adjuvanted Malaria Transplastomic Plant-Based Vaccine Induces Immune Responses in Test Animals. Molecular Biotechnology, (2020); 62534-545.
Zheng J, Pan H, Gu Y, Zuo X, Ran N, et al. Prospects for Malaria Vaccines: Pre-Erythrocytic Stages, Blood Stages, and Transmission-Blocking Stages. Biomed Research International, (2019); 20199751471.
Venkatesh V (2023) DESIGNING mRNA BASED MULTISTAGE VACCINE FOR MALARIA: Johns Hopkins University.
Haron FN, Azazi A, Chua KH, Lim YAL, Lee PC, et al. Small-scale optimization of recombinant Plasmodium knowlesi apical membrane antigen 1 (rPkAMA1) expression in Pichia pastoris. Asian Journal of Medicine and Biomedicine, (2020); 4(SI1): 79-90.
Duffy PE, Patrick Gorres J. Malaria vaccines since 2000: progress, priorities, products. npj Vaccines, (2020); 5(1): 48.
Srinivasan P, Baldeviano GC, Miura K, Diouf A, Ventocilla JA, et al. A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection. NPJ Vaccines, (2017); 2(1): 14.
Drew DR, Wilson DW, Weiss GE, Yeoh LM, I GH, et al. Defining species-specific and conserved interactions of apical membrane protein 1 during erythrocyte invasion in malaria to inform multi-species vaccines. Cellular and Molecular Life Sciences, (2023); 80(3): 74.
Thomson-Luque R, Stabler TC, Fürle K, Silva JC, Daubenberger C. Plasmodium falciparum merozoite surface protein 1 as asexual blood stage malaria vaccine candidate. Expert Review of Vaccines, (2024); 23(1): 160-173.
Rathay V, Furle K, Kiehl V, Ulmer A, Lanzer M, et al. IgG Subclass Switch in Volunteers Repeatedly Immunized with the Full-Length Plasmodium falciparum Merozoite Surface Protein 1 (MSP1). Vaccines (Basel), (2024); 12(2): 208.
Xu Q, Liu S, Kassegne K, Yang B, Lu J, et al. Genetic diversity and immunogenicity of the merozoite surface protein 1 C-terminal 19-kDa fragment (MSP119) of Plasmodium ovale imported from Africa to China. Parasites & Vectors, (2021); 14(1): 583.
Chitnis CE, Mukherjee P, Mehta S, Yazdani SS, Dhawan S, et al. Correction: Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175. PLoS One, (2015); 10(9): e0137816.
Rosenkranz M, Furle K, Hibbert J, Ulmer A, Ali A, et al. Multifunctional IgG/IgM antibodies and cellular cytotoxicity are elicited by the full-length MSP1 SumayaVac-1 malaria vaccine. NPJ Vaccines, (2023); 8(1): 112.
Dickey TH, Tolia NH. Designing an effective malaria vaccine targeting Plasmodium vivax Duffy-binding protein. Trends in Parasitology, (2023); 39(10): 850-858.
Chen E, Salinas ND, Ntumngia FB, Adams JH, Tolia NH. Structural analysis of the synthetic Duffy Binding Protein (DBP) antigen DEKnull relevant for Plasmodium vivax malaria vaccine design. PLoS Neglected Tropical Diseases, (2015); 9(3): e0003644.
Genton B, Reed ZH. Asexual blood-stage malaria vaccine development: facing the challenges. Current Opinion in Infectectious Diseases, (2007); 20(5): 467-475.
Alves KCS, Guimarães JM, Almeida MEMd, Mariúba LAM. Plasmodium falciparum merozoite surface protein 3 as a vaccine candidate: a brief review. Revista do Instituto de Medicina Tropical de São Paulo, (2022); 64e23.
Salamanca DR, Gomez M, Camargo A, Cuy-Chaparro L, Molina-Franky J, et al. Plasmodium falciparum Blood Stage Antimalarial Vaccines: An Analysis of Ongoing Clinical Trials and New Perspectives Related to Synthetic Vaccines. Frontiers in Microbiology, (2019); 102712.
Takashima E, Otsuki H, Morita M, Ito D, Nagaoka H, et al. The Need for Novel Asexual Blood-Stage Malaria Vaccine Candidates for Plasmodium falciparum. Biomolecules, (2024); 14(1): 100.
Yagi M, Palacpac NM, Ito K, Oishi Y, Itagaki S, et al. Antibody titres and boosting after natural malaria infection in BK-SE36 vaccine responders during a follow-up study in Uganda. Scientific Reports, (2016); 6(1): 34363.
Bei AK, Membi CD, Rayner JC, Mubi M, Ngasala B, et al. Variant merozoite protein expression is associated with erythrocyte invasion phenotypes in Plasmodium falciparum isolates from Tanzania. Molecular and biochemical parasitology, (2007); 153(1): 66.
Minassian AM (2018) Safety and Immunogenicity of ChAd63 RH5 and MVA RH5 in Adults, Young Children and Infants Living in Tanzania. University of Oxford. NCT03435874 NCT03435874.
Launay O, Sirima S (2013) Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults:a Staggered Phase Ia/Ib, Randomised, Double-blind, Multi-Centre Trial. NCT02014727 NCT02014727.
Daubenberger C, Olotu A. A Randomised, Controlled, Double-blind, Parallel Group, Single Center Phase Ib Trial to Assess Safety, Reactogenicity, Immunogenicity and Parasite Growth Rates After Controlled Human Malaria Infection of a Candidate Dual-stage Malaria Vaccine, SumayaVac-1 (MSP-1 With GLA-SE as Adjuvant) in Healthy Malaria Exposed Adults of African Origin Aged 18-45 Years. (2024,May10);[https://www.cms.ihi.or.tz/grants_portifolio/A%20randomised,%20controlled,%20double-blind,%20parallel%20group,%20single%20center%20Phase%20Ib%20trial%20to%20assess%20safety,%20reactogenicity,%20immunogenicity%20and%20parasite%20growth%20rates%20after%20Controlled%20Human%20Malaria%20Infection%20of%20a%20candidate%20dual-stage%20malaria%20vaccine,%20SumayaVac-1%20(MSP-1%20with%20GLA-SE%20as%20adjuvant)%20in%20healthy%20malaria%20exposed%20adults%20of%20African%20origin%20aged%2018-45%20years](https://www.cms.ihi.or.tz/grants_portifolio/A%20randomised,%20controlled,%20double-blind,%20parallel%20group,%20single%20center%20Phase%20Ib%20trial%20to%20assess%20safety,%20reactogenicity,%20immunogenicity%20and%20parasite%20growth%20rates%20after%20Controlled%20Human%20Malaria%20Infection%20of%20a%20candidate%20dual-stage%20malaria%20vaccine,%20SumayaVac-1%20(MSP-1%20with%20GLA-SE%20as%20adjuvant)%20in%20healthy%20malaria%20exposed%20adults%20of%20African%20origin%20aged%2018-45%20years).
Thera M (2023) A Phase 1b/2b Double Blind, Randomized, Controlled Study of the Safety, Immunogenicity, and Efficacy of Malaria Vaccine Candidate MSP3-CRM-Vac4All/ Alhydrogel® in Young Children in Mali. NCT05776017 NCT05776017.
Minassian AM (2019) A Phase IIa Challenge Study to Assess Efficacy of the Plasmodium Vivax Malaria Vaccine Candidates ChAd63 PvDBP and MVA PvDBP in Healthy Adults Living in the UK. NCT04009096 NCT04009096.
Koram KA, Adu B, Ocran J, Karikari YS, Adu-Amankwah S, et al. (2009) Phase I, Double-Blinded, Placebo-Controlled Dosage-Escalation Study of the Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults. NCT01026246 NCT01026246.
Cai J, Chen S, Zhu F, Lu X, Liu T, et al. Whole-Killed Blood-Stage Vaccine: Is It Worthwhile to Further Develop It to Control Malaria? Frontiers in Microbiology, (2021); 12670775.
Othman AS, Franke-Fayard BM, Imai T, van der Gracht ETI, Redeker A, et al. OX40 Stimulation Enhances Protective Immune Responses Induced After Vaccination With Attenuated Malaria Parasites. Frontiers in Cellular and Infection Microbiology, (2018); 8247.
Khan SA, Ahmad I, Khan W, Khan H, Akbar S. The contagious nature of SARS-CoV-2 omicron variant and vaccine efficacy. Advancements in Life Sciences, (2023); 9(4): 429-436.
Bonam SR, Renia L, Tadepalli G, Bayry J, Kumar HMS. Plasmodium falciparum Malaria Vaccines and Vaccine Adjuvants. Vaccines (Basel), (2021); 9(10): 1072.
Leyba AL, Razmjoo M, Francian A, Bierle A, Roberts B, et al. Overcoming Barriers of Vaccination Against Malaria Using Microneedles and TRIO. University of New Mexico (2023).
Yao X, Wu J, Lin M, Sun W, He X, et al. Increased CD40 Expression Enhances Early STING-Mediated Type I Interferon Response and Host Survival in a Rodent Malaria Model. PLoS Pathog, (2016); 12(10): e1005930.
Lee SH, Chu KB, Kang HJ, Basak S, Kim MJ, et al. Virus-like particles expressing Plasmodium berghei MSP-8 induce protection against P. berghei infection. Parasite Immunol, (2020); 42(11): e12781.
Paliwal H, Prajapati BG, Parihar A, Ganugula S, Patel JK, et al. (2023) Solid Lipid Nanoparticles in Malaria. Malarial Drug Delivery Systems: Advances in Treatment of Infectious Diseases: Springer. pp. 113-137.
Hamad TG, Salman TA. Investigation of the Impact of Environmentally Friendly prepared Alumina Nanoparticles on Bacterial Activity. Advancements in Life Sciences, (2023); 1095-100.
Imran M, Alsayeqh AF. Antiparasitic Activity of Chemically Synthesized Magnesium Oxide Nanoparticles against Small Ruminant Haemonchosis. Advancements in Life Sciences, (2022); 9(3): 356-362.
Ur Rehman A, Aminu MA, Nasir MH, Othman AS. Engineered Virus-Like Particles (VLPs): A Modern Approach to Infectious Diseases and Metabolic Disorders. Malaysian Journal of Medicine & Health Sciences, (2024); 20.
King LD, Pulido D, Barrett JR, Davies H, Quinkert D, et al. Preclinical Development of a Stabilized RH5 Virus-Like Particle Vaccine that Induces Improved Anti-Malarial Antibodies. BioRxiv, (2024); 2024.2001. 2004.574181.
Xu Y, Fourniols T, Labrak Y, Preat V, Beloqui A, et al. Surface Modification of Lipid-Based Nanoparticles. ACS Nano, (2022); 16(5): 7168-7196.
Mascola JR, Fauci AS. Novel vaccine technologies for the 21st century. Nat Rev Immunol, (2020); 20(2): 87-88.
Hu Y, Smith D, Frazier E, Zhao Z, Zhang C. Toll-like receptor 9 agonists as adjuvants for nanoparticle-based nicotine vaccine. Molecular Pharmaceutics, (2021); 18(3): 1293-1304.
Ilyas H, Afzal A, Abbas Z, Noor S, Ullah I, et al. Commands of Synthetic Biology to Modernize and Re-design the Biological Systems. Advancements in Life Sciences, (2024); 11(3): 549-557.
Terheggen U, Drew DR, Hodder AN, Cross NJ, Mugyenyi CK, et al. Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines. BMC Med, (2014); 12183.
Good MF, Stanisic DI. Whole parasite vaccines for the asexual blood stages of Plasmodium. Immunological Reviews, (2020); 293(1): 270-282.
DOI: http://dx.doi.org/10.62940/als.v12i2.3531
Refbacks
- There are currently no refbacks.